Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Common Equity (2017 - 2025)

Dianthus Therapeutics has reported Common Equity over the past 8 years, most recently at $546.5 million for Q3 2025.

  • Quarterly results put Common Equity at $546.5 million for Q3 2025, up 61.72% from a year ago — trailing twelve months through Sep 2025 was $546.5 million (up 61.72% YoY), and the annual figure for FY2024 was $352.5 million, up 108.73%.
  • Common Equity for Q3 2025 was $546.5 million at Dianthus Therapeutics, up from $303.1 million in the prior quarter.
  • Over the last five years, Common Equity for DNTH hit a ceiling of $546.5 million in Q3 2025 and a floor of -$61.5 million in Q2 2023.
  • Median Common Equity over the past 4 years was $178.4 million (2023), compared with a mean of $180.4 million.
  • Biggest five-year swings in Common Equity: tumbled 130.32% in 2023 and later skyrocketed 833.35% in 2024.
  • Dianthus Therapeutics' Common Equity stood at -$44.4 million in 2022, then skyrocketed by 480.61% to $168.9 million in 2023, then soared by 108.73% to $352.5 million in 2024, then skyrocketed by 55.03% to $546.5 million in 2025.
  • The last three reported values for Common Equity were $546.5 million (Q3 2025), $303.1 million (Q2 2025), and $328.6 million (Q1 2025) per Business Quant data.